Halcion (triazolam) is a benzodiazepine that is primarily used for the short-term treatment of insomnia. Medications within this class have a high potential for dependence and abuse, particularly when used over extended periods or not as prescribed. As such, clients taking Halcion may exhibit signs of drug addiction, such as an increased tolerance to the medication, withdrawal symptoms when not taken, or a compulsion to continue using despite negative consequences.
In contrast, the other options present medications with lower risks of addiction. Prozac (fluoxetine) is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety disorders, and it does not have addictive properties. Thorazine (chlorpromazine) is an antipsychotic used primarily to treat schizophrenia and is not associated with addiction. Depakote (valproic acid) is a mood stabilizer commonly used for bipolar disorder and seizure disorders, and it also does not carry a risk of addiction. Thus, among the options given, the focus on Halcion highlights the importance of monitoring clients for signs of addiction, especially with drugs known for their potential to lead to dependency.